Developer docs
API playgroundTry for free, no card

Search company profiles

Advanced NanoTherapies

Full company profile

uuid0002jtj

Namestring
Advanced NanoTherapies
Legal namestring
Advanced NanoTherapies, Inc.
Websiteurl
advnanot.com
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Gatos, United States
HQ citystring
Los Gatos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug-coated balloons, nanoparticle drug delivery, coronary artery disease devices, peripheral artery disease treatment, dual-drug therapy
Industry2 codes
PRIMARYHLAHAFAA
Coronary Stents & Drug-Eluting Technologies
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Research and Development in Nanotechnology541713
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Drug-Coated Balloons / Cardiovascular Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales (Future)
TypeHardware Sales
Description

Once FDA approved, the company plans to commercialize the SirPlux Duo drug-coated balloon through direct hospital/cath lab sales. Products are currently in development and not available for sale.

biospace.com
2Licensing Royalties (Potential)
TypeLicensing Royalties
Description

The drug-agnostic nanoparticle platform could generate licensing revenue from partnerships with other medical device companies seeking drug delivery solutions.

pulse2.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1SirPlux Duo
Description

Dual-drug nanoparticle-coated balloon platform for treating coronary and peripheral artery disease, combining paclitaxel and sirolimus

advancednanotherapies.com
Core offering1 text field

Advanced NanoTherapies develops the SirPlux Duo Drug Coated Balloon (DCB), a next-generation medical device that simultaneously delivers Sirolimus and Paclitaxel via proprietary biodegradable functionalized nanoparticles for treating coronary artery disease (CAD) and peripheral artery disease (PAD). The platform is exclusively licensed from Cleveland Clinic and provides sustained drug release and retention at lesion sites without leaving a permanent implant. The product is currently in clinical development and not yet available for sale, with FDA Breakthrough Device Designation granted for below-the-knee (BTK) peripheral applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • No new treatment failures over two years of follow-up in 28-patient first-in-human study
+2 more records
Product overview1 text field

Advanced NanoTherapies offers a single unified product: the SirPlux™ Duo Drug Coated Balloon (DCB), a nanoparticle-based dual-drug delivery platform. The platform is designed to deliver Sirolimus and Paclitaxel simultaneously through functionalized nanoparticles, providing higher potency and lower dosage compared to single-drug alternatives. The technology is exclusively licensed from Cleveland Clinic and is drug-agnostic, meaning the same excipient formulation can theoretically be used with other drug combinations. The product is currently in clinical development for coronary and peripheral artery disease applications, with FDA Breakthrough Device designation for below-the-knee (BTK) peripheral applications.

Product and service1 record
1SirPlux Duo Drug Coated Balloon (DCB)
CategoryCardiovascular Medical Devices - Drug-Coated Balloons
Description

A next-generation drug-coated balloon that simultaneously delivers Sirolimus and Paclitaxel via a proprietary nanoparticle drug delivery platform for treating coronary artery disease (CAD) and peripheral artery disease (PAD), including below-the-knee (BTK) applications. The product provides sustained drug release and retention at the lesion site without leaving a permanent implant, and has received FDA Breakthrough Device Designation for BTK use. Currently in clinical development and not available for sale.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-02
Description

Exclusive license agreement for proprietary nanoparticle technology enabling dual-drug delivery (paclitaxel and sirolimus) in vascular treatment applications. This is the foundational technology underlying the SirPlux Duo platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Advanced NanoTherapies

Drug-Coated Balloons / Cardiovascular Medical Devicesadvnanot.com

Advanced NanoTherapies firmographics

Firmographics
Name
Advanced NanoTherapies
Legal name
Advanced NanoTherapies, Inc.
Website
https://advnanot.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Advanced NanoTherapies industry classification

Industry
Product category
Drug-Coated Balloons / Cardiovascular Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Research and Development in Nanotechnology (541713)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAA
Coronary Stents & Drug-Eluting Technologies
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Drug-coated balloons
  • Nanoparticle drug delivery
  • Coronary artery disease devices
  • Peripheral artery disease treatment
  • Dual-drug therapy

Where Advanced NanoTherapies is headquartered

Location

Headquarters

HQ city
Los Gatos
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Advanced NanoTherapies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Medical Device Sales (Future): Once FDA approved, the company plans to commercialize the SirPlux Duo drug-coated balloon through direct hospital/cath lab sales. Products are currently in development and not available for sale.
  2. Licensing Royalties (Potential): The drug-agnostic nanoparticle platform could generate licensing revenue from partnerships with other medical device companies seeking drug delivery solutions.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Advanced NanoTherapies product offering

Product offering

Core offering

Advanced NanoTherapies develops the SirPlux Duo Drug Coated Balloon (DCB), a next-generation medical device that simultaneously delivers Sirolimus and Paclitaxel via proprietary biodegradable functionalized nanoparticles for treating coronary artery disease (CAD) and peripheral artery disease (PAD). The platform is exclusively licensed from Cleveland Clinic and provides sustained drug release and retention at lesion sites without leaving a permanent implant. The product is currently in clinical development and not yet available for sale, with FDA Breakthrough Device Designation granted for below-the-knee (BTK) peripheral applications.

Product overview

Advanced NanoTherapies offers a single unified product: the SirPlux™ Duo Drug Coated Balloon (DCB), a nanoparticle-based dual-drug delivery platform. The platform is designed to deliver Sirolimus and Paclitaxel simultaneously through functionalized nanoparticles, providing higher potency and lower dosage compared to single-drug alternatives. The technology is exclusively licensed from Cleveland Clinic and is drug-agnostic, meaning the same excipient formulation can theoretically be used with other drug combinations. The product is currently in clinical development for coronary and peripheral artery disease applications, with FDA Breakthrough Device designation for below-the-knee (BTK) peripheral applications.

Differentiator

Problem solved

Functional benefit

Brands

  • SirPlux Duo: Dual-drug nanoparticle-coated balloon platform for treating coronary and peripheral artery disease, combining paclitaxel and sirolimus

Products and services

  • SirPlux Duo Drug Coated Balloon (DCB) A next-generation drug-coated balloon that simultaneously delivers Sirolimus and Paclitaxel via a proprietary nanoparticle drug delivery platform for treating coronary artery disease (CAD) and peripheral artery disease (PAD), including below-the-knee (BTK) applications. The product provides sustained drug release and retention at the lesion site without leaving a permanent implant, and has received FDA Breakthrough Device Designation for BTK use. Currently in clinical development and not available for sale.

Quantifiable outcome

  • No new treatment failures over two years of follow-up in 28-patient first-in-human study
  • +2 more outcomes

Companies that use Advanced NanoTherapies

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Advanced NanoTherapies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Advanced NanoTherapies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cleveland CliniccoreTechnology or Integration · 2 June 2026Exclusive license agreement for proprietary nanoparticle technology enabling dual-drug delivery (paclitaxel and sirolimus) in vascular treatment applications. This is the foundational technology underlying the SirPlux Duo platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Advanced NanoTherapies competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

Advanced NanoTherapies social profiles

Digital presence

Advanced NanoTherapies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Advanced NanoTherapies leadership team

Management profile

Number of profiles

Profiles3 records

Advanced NanoTherapies funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Advanced NanoTherapies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced NanoTherapies

What does Advanced NanoTherapies do?

Advanced NanoTherapies develops the SirPlux Duo Drug Coated Balloon (DCB), a next-generation medical device that simultaneously delivers Sirolimus and Paclitaxel via proprietary biodegradable functionalized nanoparticles for treating coronary artery disease (CAD) and peripheral artery disease (PAD). The platform is exclusively licensed from Cleveland Clinic and provides sustained drug release and retention at lesion sites without leaving a permanent implant. The product is currently in clinical development and not yet available for sale, with FDA Breakthrough Device Designation granted for below-the-knee (BTK) peripheral applications.

Is Advanced NanoTherapies a public or private company?

Advanced NanoTherapies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Advanced NanoTherapies founded?

Advanced NanoTherapies was founded in 2020. It employs 11 to 50 people.

Where is Advanced NanoTherapies based?

Advanced NanoTherapies is headquartered in Los Gatos, United States, in the North America region.

How does Advanced NanoTherapies make money?

Two revenue lines are on record. Medical Device Sales (Future) is the primary driver. The others are licensing Royalties (Potential).

Does Advanced NanoTherapies have an API?

No public API is recorded for Advanced NanoTherapies.

What industry is Advanced NanoTherapies in?

Advanced NanoTherapies's product category is Drug-Coated Balloons / Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAA, Coronary Stents & Drug-Eluting Technologies, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Third NewsEnlil Achieves Record-Setting Q2 2026 Amid Strong Customer Growth and ExpansionsEnlil, Inc. achieved its strongest revenue quarter in Q2 2026, adding five new customers while existing clients renewed and expanded their subscriptions on its AI-driven development traceability platform for medical device and life sciences organizations. Swan EndoSurgical Robotics extended its multi-year agreement and broadened its user base by integrating additional Enlil features including SolidWorks API, Milestone View, and Ask Lily. The company also onboarded new customers including Advanced NanoTherapies (backed by T45 Labs) and Los Angeles Biosciences, which switched from a competing quality management system, signaling demand for flexible solutions in the MedTech sector.BioWorldFinancings for June 4, 2026Biopharma and med-tech companies including Advanced Nanotherapies, Bluejay, Liminatus, Lixte, Medtronic, Mineralys, and Nrx raised money in public or private financings on June 4, 2026. The list covers both public and private financing rounds.Pulse 2.0Advanced NanoTherapies Raises Over $31 Million Series B To Advance Dual-Drug Nanoparticle-Coated Balloon PlatformAdvanced NanoTherapies (ANT) announced the closing of an oversubscribed Series B financing round totaling more than $31 million, co-led by an undisclosed strategic investor and S3 Ventures with participation from the T45 Fund and other new and existing investors. The funding will support U.S. regulatory and clinical milestones for ANT's lead product SirPlux Duo, including FDA Investigational Device Exemption (IDE) approvals, advancement of coronary clinical programs, and expansion into below-the-knee peripheral artery disease applications. ANT's nanoparticle-based drug-coated balloon platform combines paclitaxel and sirolimus, exclusively licensed from Cleveland Clinic, and has received FDA Breakthrough Device designation though it is not yet commercially approved.BioSpaceAdvanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular TreatmentAdvanced NanoTherapies closed an oversubscribed Series B financing of over $31 million, co-led by an undisclosed strategic investor and S3 Ventures. The funds will support U.S. IDE approvals and clinical advancement of its dual-drug nanoparticle-coated balloon platform, SirPlux Duo, which has received FDA breakthrough designation.PR NewswireAdvanced NanoTherapies sichert sich über 31 Millionen US-Dollar in der Serie-B-Finanzierungsrunde, um eine einzigartige Plattform mit einem mit Nanopartikeln beschichteten Ballon für die vaskuläre BehAdvanced NanoTherapies, a clinical-stage medical device company, closed an oversubscribed Series B funding round totaling more than $31 million, co-led by S3 Ventures and a strategic investor with participation from the T45 Fund. The funds will support FDA Investigational Device Exemption (IDE) acquisition, clinical development of the SirPlux Duo drug-coated balloon for coronary applications, and expansion into below-the-knee peripheral vascular treatments. The company's lead program has received FDA Breakthrough Therapy designation and is being developed on a nanoparticle platform licensed exclusively from Cleveland Clinic, with clinical data from early human studies in Australia, the Dominican Republic, and New Zealand supporting the regulatory pathway.PR NewswireAdvanced NanoTherapies desarrollará una plataforma de balón recubierto de nanopartículas con doble fármacoAdvanced NanoTherapies, Inc. closed an oversubscribed Series B funding round totaling over $31 million to develop SirPlux Duo, a dual-drug nanoparticle-coated balloon platform (paclitaxel and sirolimus) for treating coronary and peripheral artery disease. The round was co-led by S3 Ventures and an undisclosed strategic investor, with participation from T45 Fund, and will support FDA Investigational Device Exemption (IDE) applications and clinical advancement in the United States. The technology, exclusively licensed from Cleveland Clinic, has received FDA Breakthrough Therapy Designation and is currently in clinical evaluation across studies in Australia, the Dominican Republic, New Zealand, and Spain.PR NewswireAdvanced NanoTherapies obtient plus de 31 millions de dollars de série B pour proposer le premier ballon enrobé de deux médicament (paclitaxel et sirolimus) recouvert de nanoparticules pour le traitemAdvanced NanoTherapies, Inc. (ANT) has closed an oversubscribed Series B funding round totaling more than $31 million, co-led by an undisclosed strategic investor and S3 Ventures, with participation from T45 and other investors. The funding will support IDE (Investigational Device Exemption) approval in the United States, advancement of coronary clinical trials, and expansion of below-the-knee (BTK) peripheral applications for the company's SirPlux Duo dual-drug balloon technology. The device, which uses a proprietary nanoparticle delivery system to co-deliver paclitaxel and sirolimus, has received FDA breakthrough designation and is licensed exclusively from the Cleveland Clinic.citybizAdvanced NanoTherapies Raises $31 Million to Advance Novel Dual-Drug Vascular TherapyAdvanced NanoTherapies has closed a $31 million oversubscribed Series B financing round co-led by S3 Ventures and an undisclosed strategic investor, with participation from the T45 Fund, to advance clinical development of its SirPlux Duo dual-drug vascular intervention platform. The technology, exclusively licensed from Cleveland Clinic and featuring a biodegradable nanoparticle delivery of sirolimus and paclitaxel, has received FDA Breakthrough Device designation and is being developed for coronary and peripheral artery disease applications. Clinical data from a 28-patient first-in-human study across Australia, New Zealand, and the Dominican Republic showed no new treatment failures over two years of follow-up, with a 30-patient Spain study ongoing.PR NewswireAdvanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular TreatmentAdvanced NanoTherapies, a clinical-stage medtech company, closed an oversubscribed Series B financing round totaling more than $31 million, co-led by S3 Ventures and an undisclosed strategic investor, with participation from the T45 Fund and other investors. The funding will support U.S. IDE approval, advancement of its dual-drug SirPlux Duo nanoparticle platform (paclitaxel and sirolimus) in coronary and peripheral artery disease indications, and manufacturing scale-up. The technology is exclusively licensed from Cleveland Clinic, has received FDA breakthrough designation, and is currently in clinical evaluation with first-in-human data from 28 patients in Australia, the Dominican Republic, and New Zealand.PR NewswireAdvanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular TreatmentAdvanced NanoTherapies, Inc. (ANT) announced the closing of an oversubscribed Series B financing totaling more than $31 million, co-led by S3 Ventures and an undisclosed strategic investor, with participation from T45 Fund and other investors. The funding will support U.S. FDA Investigational Device Exemption approval, advancement of coronary clinical programs, and expansion into below-the-knee peripheral applications for the company's SirPlux Duo dual-drug nanoparticle-coated balloon platform. ANT's lead program has received FDA breakthrough designation and is under clinical evaluation across studies in Australia, the Dominican Republic, New Zealand, and Spain.